What’s Actually at Risk
When commissioning custom peptide synthesis, buyers typically share the peptide sequence itself, and sometimes additional context about intended application or formulation, with the manufacturer. Both the sequence and the process knowledge the manufacturer develops while synthesizing it represent potential intellectual property exposure, and buyers should think through both categories separately when structuring protection.
For peptides not yet covered by an issued patent, sequence confidentiality is particularly important, since public disclosure, even inadvertent disclosure to a manufacturer without adequate confidentiality protection, can affect the buyer’s own future patent eligibility in some jurisdictions.
Confidentiality Agreements That Actually Protect You
A mutual non-disclosure agreement is the baseline protection, but buyers should review the specific terms carefully rather than accepting a manufacturer’s standard template without modification, particularly regarding the duration of confidentiality obligations, what happens to the sequence information if the relationship ends, and whether the manufacturer is restricted from synthesizing the identical sequence for other clients.
It is reasonable to request destruction or return of sequence information and any samples if a project does not proceed to a full order, and to specify this explicitly in the agreement rather than assuming it happens automatically.
Process Know-How and Exclusivity
Manufacturers naturally develop process knowledge while synthesizing a novel sequence, and by default, many retain the right to apply general process improvements to other work, even if the specific sequence itself remains confidential. Buyers with strong exclusivity needs should negotiate explicit terms covering whether the manufacturer can synthesize the same or a substantially similar sequence for a third party, and for how long this restriction applies.
This kind of exclusivity typically carries a commercial cost, since it constrains the manufacturer’s ability to use its capacity flexibly, and buyers should expect this to be reflected in pricing or minimum volume commitments rather than treated as a standard, cost-free term.
Patent Filing Coordination
For sequences intended for patent protection, coordinating the timing of manufacturer engagement with the patent filing process matters, since some jurisdictions have grace periods for inventor disclosures but stricter rules around third-party disclosure. Buyers should consult patent counsel about appropriate timing before sharing a sequence with any manufacturer, rather than assuming a standard non-disclosure agreement fully resolves this consideration.
Once a patent application has been filed, sharing the sequence with a manufacturer under confidentiality generally becomes more straightforward from an IP protection standpoint, which is why some buyers deliberately sequence their manufacturer engagement to follow, rather than precede, an initial patent filing.